stockportfolio.pro
Surgery Partners, Inc. (SGRY)
Healthcare · Medical Care Facilities · NasdaqGS
Surgery Partners, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959.89M | $1.15B | $1.77B | $1.83B | $1.86B | $2.23B | $2.54B | $2.74B | $3.11B | $3.31B |
| Gross profit | $290.56M | $324.24M | $410.10M | $423.80M | — | — | $574.90M | $647.50M | $745.60M | $765.00M |
| Net income | $1.43M | $9.45M | $-205.70M | $-74.80M | $-116.10M | $-70.90M | $-54.60M | $-11.90M | $-168.10M | $-77.90M |
| Net margin | 0.1% | 0.8% | -11.6% | -4.1% | -6.2% | -3.2% | -2.2% | -0.4% | -5.4% | -2.4% |
Source: Surgery Partners, Inc. SEC filings (10-K). 12 years of history available in the interactive view.
What growth is priced into SGRY stock?
At today's market cap of $1.94B, Surgery Partners, Inc. is priced for free-cash-flow growth of about -2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $195.60M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.8%/yr over the last five fiscal years and revenue 12.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 12 years of Surgery Partners, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SGRY in your portfolio →
Surgery Partners, Inc. financial history by metric
About Surgery Partners, Inc.
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Surgery Partners, Inc. — frequently asked questions
What is Surgery Partners, Inc.'s revenue?
Surgery Partners, Inc. (SGRY) reported revenue of $3.31B for fiscal year 2025, up 6.2% from the prior year, according to its SEC filings.
Is Surgery Partners, Inc. profitable?
No — SGRY reported a net loss of $-77.90M in fiscal 2025.
What is SGRY's P/E ratio?
Surgery Partners, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Surgery Partners, Inc. growing?
SGRY's revenue grew at roughly 12.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Surgery Partners, Inc. have?
As of fiscal year 2025, SGRY carried roughly $3.70B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Surgery Partners, Inc.'s gross margin?
SGRY's gross margin was 23.1% in fiscal 2025 — gross profit of $765.00M on revenue of $3.31B.
What is Surgery Partners, Inc.'s market cap?
Surgery Partners, Inc. (SGRY) has a market capitalization of about $1.94B, based on the latest data in our nightly-refreshed cache.
When does Surgery Partners, Inc.'s fiscal year end?
SGRY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into SGRY stock?
At today's market cap of $1.94B, Surgery Partners, Inc. is priced for free-cash-flow growth of about -2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $195.60M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.8%/yr over the last five fiscal years and revenue 12.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Surgery Partners, Inc.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.